Engineered psychedelic analog in mice retains antidepressant-like and anti-inflammatory effects while avoiding the severe gastrointestinal distress seen with ibogaine

A newly engineered psychedelic analog shows therapeutic promise in preclinical research while avoiding the intense gastrointestinal side effects that limit ibogaine's medical use. The compound was designed to preserve beneficial brain and anti-inflammatory actions without triggering the vomiting and digestive distress commonly associated with ibogaine. Mouse findings indicate antidepressant-like effects and reduced inflammation, suggesting potential relevance for mood disorders and other conditions where ibogaine-related mechanisms may help. The safety profile is central because gastrointestinal toxicity has been a major obstacle to turning ibogaine-inspired compounds into practical treatments. This line of research reflects a broader effort to create next-generation psychedelics that keep therapeutic benefits while reducing physiological burden and improving tolerability for eventual clinical development.